01 October 2021 : Original article
Outcomes After Living Donor Liver Transplantation in Pediatric Patients with Inherited Metabolic Diseases
Yukihiro Sanada1ABCDEF*, Yasunaru Sakuma1DF, Yasuharu Onishi1B, Noriki Okada1B, Naoya Yamada1B, Yuta Hirata1B, Go Miyahara1B, Takumi Katano1B, Toshio Horiuchi1B, Takahiko Omameuda1B, Alan Kawarai Lefor
1DF, Naohiro Sata1DF
DOI: 10.12659/AOT.932994
Ann Transplant 2021; 26:e932994
Table 2 Univariate analysis of risk factors for post-transplant complications in recipients with IMDs and BA.
| Variable | Recipients with IMDsN=44 | Recipients with BAN=221 | p-value |
|---|---|---|---|
| Hepatic vein complications | 2 (4.5%) | 15 (6.8%) | 0.746 |
| Portal vein complications | 4 (9.1%) | 38 (17.2%) | 0.257 |
| Hepatic artery complications | 2 (4.5%) | 11 (5.0%) | 0.999 |
| Biliary complications | 8 (18.2%) | 45 (20.4%) | 0.839 |
| Re-laparotomy after LDLT | 7 (15.9%) | 22 (10.0%) | 0.288 |
| Acute cellular rejection | 12 (27.3%) | 98 (44.3%) | 0.044 |
| Steroid-resistant acute rejection | 1 (2.3%) | 26 (11.8%) | 0.059 |
| Cytomegalovirus viremia | 22 (50.0%) | 73 (33.0%) | 0.039 |
| Post-transplant lymphoproliferative disorder | 0 (0%) | 6 (2.7%) | 0.594 |
| Hospital length of stay | 62±107 days | 43±30 days | 0.125 |
| IMDs – inherited metabolic diseases; BA – biliary atresia; LDLT – living donor liver transplantation. | |||